{"preliminary_commentary":{"by_channel":{"bluesky_thread":2,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT05936359","nct_id":"NCT05936359","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05936359. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"INCA033989 will be administered at a protocol defined starting regimen in 28-day cycles as monotherapy to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE\\[s\\]). Participants with myelofibrosis (MF) will enroll in this group.","label":"Part 1a Dose Escalation Cohort Disease Group A - with MF","type":"EXPERIMENTAL"},{"description":"INCA033989 will be administered at a protocol defined starting regimen in 28-day cycles as monotherapy to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE\\[s\\]). Participants with with essential thrombocythemia (ET) will enroll in this group.","label":"Part 1a Dose Escalation Cohort Disease Group A - with ET","type":"EXPERIMENTAL"},{"description":"INCA033989 will be administered at a protocol defined starting regimen in 28- day cycles and will allow for the evaluation of INCA033989 in combination with ruxolitinib to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE\\[s\\]). Participants with myelofibrosis (MF) exhibiting suboptimal response (SubOpt R) will enroll in this group.","label":"Part 1a: Dose Escalation Cohort Disease Group B - with TGB-MF SubOpt R","type":"EXPERIMENTAL"},{"description":"INCA033989 will be administered as monotherapy at the RDE(s) identified during Part 1a. Participants with treatment group A (TGA) myelofibrosis MF will enroll in this group.","label":"Part 1b: Dose Expansion - with MF","type":"EXPERIMENTAL"},{"description":"INCA033989 will be administered as an add-on therapy in combination with ruxolitinibat at the RDE(s) identified during Part 1a. Participants with treatment Group B (TGB) MF SubOpt R will enroll in this group.","label":"Part 1b: Dose Expansion - with TGB-MF SubOpt R","type":"EXPERIMENTAL"},{"description":"INCA033989 will be administered as monotherapy at the RDE(s) identified during Part 1a. Participants with treatment group A (TGA) essential thrombocythemia (ET) will enroll in this group.","label":"Part 1b: Dose Expansion - with ET","type":"EXPERIMENTAL"},{"description":"INCA033989 will be administered at the dose level found to exhibit an overall positive benefit/risk as monotherapy or as combination therapy with Ruxolitinib. Participants with myelofibrosis (MF) will enroll in this group. The participants enrolled in the monotherapy arm will be offered the option to crossover to combination therapy with ruxolitinib if a suboptimal response to monotherapy is observed after 12 weeks.","label":"Part 1c: Dose Expansion","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-02-29","type":"ESTIMATED"},"conditions":["Myeloproliferative Neoplasms"],"enrollment":{"count":160,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"INCA033989","otherNames":[],"type":"DRUG"},{"name":"Ruxolitinib","otherNames":["Jakafi"],"type":"DRUG"}],"last_update":"2026-08-10","lead_sponsor":"Incyte Corporation","official_title":"A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2028-02-29","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Number of participants with Dose Limiting Toxicities (DLTs)","timeFrame":"Up to 28 days"},{"measure":"Number of participants with Treatment-emergent Adverse Events (TEAEs)","timeFrame":"Up to 3 years and 60 days"},{"measure":"Number of participants with TEAEs leading to dose modification or discontinuation","timeFrame":"Up to 3 years and 60 days"}],"references":[],"start_date":{"date":"2023-09-25","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms","url":"https://clinicaltrials.gov/study/NCT05936359"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05936359"}